Egypt’s Rheumatoid Arthritis drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Rheumatoid arthritis is a chronic inflammatory, an autoimmune disorder in which can affect joints as well as several other body parts such as skin, eyes, lungs, and blood vessels. Rheumatoid arthritis affects the lining of joints, causing a painful inflammation that can eventually result in bone erosion and joint deformity.
Egypt has had low prevalence rates of Rheumatoid Arthritis, last reported to be about 0.29%, but they have been gradually rising since. Such rising prevalence and new products in the pipeline are set to determine the growth for the market in Egypt.
The Rheumatoid Arthritis market in Egypt is expected to rise steadily in the forecast period. With Egypt’s rising population and changing lifestyle, the disease prevalence is steadily rising which will impact the market growth.
Rising awareness amongst people will increase demands for newer and better treatment modes for the disease in the country.